Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm

▤ Summary

Kuehn Law is investigating whether Ultragenyx Pharmaceutical officers and directors breached fiduciary duties tied to disclosures about setrusumab. The claim centers on allegations that the company overstated or failed to disclose the drug’s true potential and study risks. The article targets current shareholders and invites them to contact the law firm if they bought shares before August 3, 2023. This is a legal notice, not a product, financing, or corporate leadership announcement.

▦ Linked Companies